Novavax Inc. (NVAX) legal chief updates 152,000-share stock option terms

Rhea-AI Filing Summary

Novavax Inc. executive Mark J. Casey reported an amended stock option grant. The Form 4/A updates only the exercise price originally reported for a non-statutory stock option covering 152,000 shares that was granted on March 2, 2026; all other details from the earlier filing remain the same.

The option was granted at no cash cost per option share and is held directly. One quarter of the 152,000 option shares vests on the first anniversary of March 2, 2026, and the remaining three quarters vest in equal monthly installments over the following three years, subject to continued employment.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Casey Mark J

Role EVP, Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Non-Statutory Stock Option NQ	152,000	$0.00	--

Holdings After Transaction: Non-Statutory Stock Option NQ — 152,000 shares (Direct)

Footnotes (1)

1. This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Casey Mark J

(Last) (First) (Middle)

21 FIRSTFIELD ROAD

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Statutory Stock Option NQ	$10.11(1)	03/02/2026		A		152,000		(2)	03/02/2036	Common Stock	152,000	$0(1)	152,000	D

Explanation of Responses:

1. This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing.

2. One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

	/s/ Mark J. Casey	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Novavax (NVAX) EVP Mark J. Casey report in this Form 4/A?

He reports an amended non-statutory stock option grant for 152,000 shares. The amendment solely corrects the exercise price previously reported, while all other information from the March 3, 2026 Form 4 remains unchanged.

Why was Novavax (NVAX) executive Mark J. Casey’s Form 4 amended?

The Form 4 was amended solely to update the exercise price reported for the stock option. The filing states that only the price in specified columns is corrected, and all other details from the original March 3, 2026 report are unchanged.

How many Novavax (NVAX) option shares did Mark J. Casey acquire?

He was granted a non-statutory stock option covering 152,000 shares. After this grant, his reported derivative holdings for this option total 152,000 shares, reflecting the full award granted on March 2, 2026 under the company plan.

What is the vesting schedule for Mark J. Casey’s Novavax (NVAX) stock option?

One quarter of the 152,000 option shares vests on the first anniversary of March 2, 2026. The remaining three quarters vest in equal monthly installments over the next three years, contingent on continued employment with Novavax through each vesting date.

Is Mark J. Casey’s Novavax (NVAX) option grant a direct holding?

Yes, the filing classifies the option as a direct holding. The ownership code is listed as “D,” and no footnotes indicate that another entity, such as a trust or LLC, holds voting or investment authority over this specific derivative security.

Does the Novavax (NVAX) Form 4/A change any terms besides the option price?

No, it explicitly states the amendment only updates the exercise price information. All other details from the March 3, 2026 Form 4, including the 152,000-share size and vesting schedule, remain unchanged according to the filing text.